Phase II trial of erlotinib in patients with bronchioloalveolar carcinoma

被引：4
|
作者：
Sandler, A
Kris, M
Miller, V
Carbone, D
Pao, W
Billheimer, D
Tsao, A
Patel, J
Johnson, B
Johnson, D
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Northwestern Univ, Chicago, IL 60611 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80243-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [1] EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial.
    Kris, MG
    Sandler, A
    Miller, VA
    Zakowski, MF
    Pao, W
    Tsao, A
    Patel, JD
    Johnson, DH
    Carbone, DP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 627S - 627S
  • [2] Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).
    Kris, MG
    Sandler, A
    Miller, V
    Cespon, M
    Zakowski, M
    Pizzo, B
    Venkatraman, E
    Gomez, J
    Johnson, D
    Carbone, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [3] Phase II trial of pemetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma
    Ho, Cheryl
    Ross, Helen
    Davies, Angela
    [J]. CLINICAL LUNG CANCER, 2006, 8 (03) : 220 - 222
  • [4] Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Schwert, RC
    Carrell, DL
    Hubbard, F
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [5] A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma
    Bedano, P. M.
    Perkins, S.
    Burns, M.
    Kessler, K.
    Nelson, R.
    Schneider, B. P.
    Risley, L.
    Dropcho, S.
    Loehrer, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
    Scagliotti, GV
    Smit, E
    Bosquee, L
    O'Brien, M
    Ardizzoni, A
    Zatloukal, P
    Eberhardt, W
    Smid-Geirnaerdt, M
    de Bruin, HG
    Dussenne, S
    Legrand, C
    Giaccone, G
    [J]. LUNG CANCER, 2005, 50 (01) : 91 - 96
  • [7] Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
    Propper, D.
    Davidenko, I.
    Bridgewater, J.
    Kupcinskas, L.
    Fittipaldo, A.
    Hillenbach, C.
    Klughammer, B.
    Ducreux, M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (07) : 1384 - 1390
  • [8] Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
    Thomas, Melanie B.
    Morris, Jeffrey S.
    Chadha, Romil
    Iwasaki, Michiko
    Kaur, Harmeet
    Lin, Elinor
    Kaseb, Ahmed
    Glover, Katrina
    Davila, Marta
    Abbruzzese, James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 843 - 850
  • [9] Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
    Horowitz, N. S.
    Olawaiye, A. B.
    Borger, D. R.
    Growdon, W. B.
    Krasner, C. N.
    Matulonis, U. A.
    Liu, J. F.
    Lee, J.
    Brard, L.
    Dizon, D. S.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 141 - 146
  • [10] Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Miller, Vincent A.
    Riely, Gregory J.
    Zakowski, Maureen F.
    Li, Allan R.
    Patel, Jyoti D.
    Heelan, Robert T.
    Kris, Mark G.
    Sandler, Alan B.
    Carbone, David P.
    Tsao, Anne
    Herbst, Roy S.
    Heller, Glenn
    Ladanyi, Marc
    Pao, William
    Johnson, David H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1472 - 1478
12345